Translate Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 13th of September, 2021.
133 hedge funds and large institutions have $1.19B invested in Translate Bio, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 68 funds opening new positions, 46 increasing their positions, 11 reducing their positions, and 9 closing their positions.
656% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 9
318% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 11
127% more capital invested
Capital invested by funds: $525M → $1.19B (+$666M)
80% more funds holding
Funds holding: 74 → 133 (+59)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
27% more call options, than puts
Call options by funds: $6.25M | Put options by funds: $4.94M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.9M |
| 2 |
BlackRock
New York
|
+$22.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 4 |
Millennium Management
New York
|
+$17.6M |
| 5 |
KSCM
Key Square Capital Management
Stamford,
Connecticut
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$24.3M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$11.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.42M |
| 4 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$2.7M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.47M |
TBIO Hedge Fund Activity: Q2 2020 in Review
133 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Translate Bio, Inc. Common Stock (TBIO) for Q2 2020, worth a combined $1.19B — up 127% from $525M a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new TBIO positions and 9 closed out — a net gain of 59 holders — while 46 added to existing stakes and 11 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $26.9M. The largest seller was Omega Fund Management, exiting entirely with an estimated $24.3M sold.
- 133 institutional investors held Translate Bio, Inc. Common Stock (TBIO) as of Q2 2020, up from 74 in Q1 2020.
- Funds reported $1.19B of Translate Bio, Inc. Common Stock stock for Q2 2020, up 127% quarter-over-quarter.
- 68 funds opened new Translate Bio, Inc. Common Stock positions in Q2 2020 and 9 closed out, a net change of +59 holders.
- The largest Translate Bio, Inc. Common Stock buyer in Q2 2020 was T. Rowe Price Associates, an estimated $26.9M added.
- The largest Translate Bio, Inc. Common Stock seller in Q2 2020 was Omega Fund Management, an estimated $24.3M sold.
Based on aggregated 13F filings for Q2 2020.